← Back to Search

Information Sharing for Chronic Kidney Disease

N/A

Recruiting

Led By Navdeep Tangri, MD PhD FRCPC

Research Sponsored by University of Manitoba

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

All patients with CKD Stages G3-G5 who attend the 32 clinics.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months after intervention

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether providing patients with information about their risk of kidney failure improves quality of care, health literacy, and trust in the care they are receiving.

Who is the study for?

This trial is for adults with moderate to severe chronic kidney disease (CKD Stages G3-G5) who are treated at primary care clinics in Manitoba and Alberta that use an electronic medical record system capable of integrating the kidney failure risk equation (KFRE).

What is being tested?

The study tests if providing personalized information about kidney failure risk, alongside usual care, improves patient care. Clinics will either integrate this approach or continue with standard care without personalized risk info.

What are the potential side effects?

Since this intervention involves knowledge translation rather than medication, traditional side effects aren't expected. However, there may be impacts on patients' emotional well-being due to awareness of their CKD progression risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have chronic kidney disease between stages 3 to 5.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months after intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months after intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months after intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of CKD patients in each clinic who have albuminuria (albumin-creatinine ratio (ACR)) tested

The percentage of patients who are appropriately managed with an ACEi or ARB, and who either have CKD and diabetes, or who have CKD and a urine ACR >30 mg/mmol.

Secondary study objectives

Appropriate medication usage

Appropriate referral for patients at high risk for kidney failure

Clinical provider's satisfaction with the risk prediction tools and clinical decision aids.

+7 more